- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05561985
Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease
October 18, 2023 updated by: Incyte Corporation
Expanded access use of Itacitinib to treat a single patient with aplastic anemia.
Study Overview
Status
Available
Conditions
Intervention / Treatment
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Incyte Corporation Call Center (US)
- Phone Number: 1.855.463.3463
- Email: medinfo@incyte.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Description
Inclusion Criteria:
-
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lisa Forbes Satter, MD, Baylor College of Medicine - Texas Children's Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
September 22, 2022
First Submitted That Met QC Criteria
September 29, 2022
First Posted (Actual)
September 30, 2022
Study Record Updates
Last Update Posted (Actual)
October 19, 2023
Last Update Submitted That Met QC Criteria
October 18, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- I-39110-19-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on STAT1 Gain-of-Function Disease
-
Centre Hospitalier Departemental VendeeRecruitingRecovery of FunctionFrance
-
University Hospital, Strasbourg, FranceUnknownRecovery of FunctionFrance
-
Université de SherbrookeCompleted
-
Sahlgrenska University Hospital, SwedenCompletedRenal Function Disorder | Complication of Extracorporeal Circulation | Kidney Circulation DisorderSweden
-
Peking University Third HospitalUnknown
-
Guy's and St Thomas' NHS Foundation TrustAstellas Pharma Europe Ltd.Unknown
-
Stanford UniversityCompletedFunction of Renal TransplantUnited States
-
Nantes University HospitalTerminated
-
National Taiwan University HospitalCompletedAlteration of Cognitive FunctionTaiwan
-
Northumbria UniversityCompletedAlteration of Cognitive FunctionUnited Kingdom
Clinical Trials on Itacitinib
-
Incyte CorporationCompletedRheumatoid ArthritisUnited States, Puerto Rico
-
Incyte CorporationActive, not recruitingB-cell MalignanciesUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingSystemic SclerosisFrance
-
Incyte CorporationTerminatedBronchiolitis Obliterans SyndromeUnited States, Belgium, Canada
-
Incyte CorporationCompletedPolycythemia Vera | Myelofibrosis | ThrombocythemiaSpain, United States, Germany, Austria, Belgium, Italy, Poland
-
Imperial College LondonIncyte Biosciences UK LtdActive, not recruitingAdvanced Hepatocellular CarcinomaUnited Kingdom
-
John LevineCompletedGVHD | Low Risk Acute Graft-versus-host Disease | Graft-versus-host-diseaseUnited States
-
Incyte CorporationCompletedMPN (Myeloproliferative Neoplasms)Canada, United States, Australia
-
Incyte CorporationActive, not recruitingChronic Graft Versus Host Disease | Myelofibrosis | Postlung Transplant (Bronchiolitis Obliterans)United States, Spain, Italy, Germany, Belgium, Austria, Israel, Canada, Greece
-
Columbia UniversityIncyte CorporationTerminatedGraft Vs Host Disease | Steroid Refractory GVHDUnited States